Increased levels of KL-6 in COVID-19 patients were associated with a more severe lung disease.<h4>Discussion and conclusion</h4>Our results suggest that KL-6 could be a good biomarker to assess ILD severity in COVID-19 infection. The gene discussed is MUC1; the disease is COVID-19.